Cardiac Regeneration – What Science Can Do – AstraZeneca

The partnership dates back to March 2013, when Moderna Therapeutics and AstraZeneca signed a five year exclusive option agreement to apply the companys platform in the search for new ways to treat cardiovascular and other diseases. In preparation for the first in-human safety studies the two companies are now working towards taking a mRNA therapeutic candidate through toxicology studies while addressing further in vivo proof of concept and targeted delivery. Ken and I speak several times a week to keep the programme moving and to discuss novel applications of this fascinating technology, says Dr Fritsche-Danielson.

Other significant collaboration partners include the University of Singapore, Shanghai Institute of Biological Sciences and the University of Virginia that all contribute to advancing the programme. The challenge is to keep connected, the field moves fast. Its not just about finding new compounds, you need to think further ahead. At AstraZeneca, we have a good academic collaboration culture, says Dr Gabriella Broln, Senior Scientist in AstraZenecas Discovery Sciences department.

Helping the team shed light on the disease by linking patient phenotypes to the different types of heart failure is a collaboration with Singapores Agency for Science, Technology and Research (A*STAR), National University Heart Centre, and National University of Singapore. The collaboration will draw data from Singapores ethnically-diverse, patient population. The focus will be on heart failure patients with preserved ejection fraction (HFpEF), which comprises almost half the heart failure population.

Here is the original post:

Cardiac Regeneration - What Science Can Do - AstraZeneca